Benjamin Bikman
ON THE RECORD · 4 verbatim quotes · every quote source-verified
“These are encouraging results,”
Benjamin Bikman · said date not stated · reported 2026-10-02
Bikman commented on Lilly's Phase 2 trial showing that eloralintide combined with tirzepatide produced 23.3% average weight loss at 48 weeks.
“Adults with type 2 diabetes typically lose less weight on these therapies than those without diabetes.”
Benjamin Bikman · said date not stated · reported 2026-10-02
Bikman noted that adults with type 2 diabetes typically lose less weight on obesity therapies than those without diabetes.
“A therapy is only effective if patients can remain on it, so tolerability in Phase 3 will be as important as efficacy,”
Benjamin Bikman · said date not stated · reported 2026-10-02
Bikman emphasized the importance of tolerability in Phase 3 trials after the Phase 2 study showed higher discontinuation rates for the combination regimen.
“It's the same outcome, but a different approach,”
Benjamin Bikman · said date not stated · reported 2026-10-02
Bikman told CNBC that amylin and GLP-1 produce similar outcomes through different biological pathways.